Evidence map›Paper›PMID 31112371›Full record

ArticleJournal of applied clinical medical physics2019

Dosimetric comparison of distal esophageal carcinoma plans for patients treated with small-spot intensity-modulated proton versus volumetric-modulated arc therapies.

Chenbin Liu, Ronik S Bhangoo, Terence T Sio, Nathan Y Yu, Jie Shan, Jennifer S Chiang, Julia X Ding, William G Rule, Shawn Korte, Pedro Lara and 6 more

Abstract readComparative Study
In one paragraph

Article in Journal of applied clinical medical physics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Technical Considerations on Proton Therapy in NRG's Multi-Institutional Clinical Trials.International journal of radiation oncology, biology, physics · 2026
    Guideline
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chenbin LiuDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Ronik S BhangooDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Terence T SioDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Nathan Y YuDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Jie ShanDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Jennifer S ChiangDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Julia X DingDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
William G RuleDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Shawn KorteDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Pedro LaraDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Xiaoning DingDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Martin BuesDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Yanle HuDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Todd DeWeesDivision of Biostatistics, Mayo Clinic, Phoenix, AZ, 85054, USA.
Jonathan B AshmanDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.
Wei LiuDepartment of Radiation Oncology, Mayo Clinic, Phoenix, AZ, 85054, USA.

Funding

4D Robust Optimization in Intensity-Modulated Proton TherapyK25CA168984 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIU, WEI · 2012 to 2015
$450k
Arizona Biomedical Research CommissionKemper Marley FoundationLawrence W. and Marilyn W. Matteson FundNational Cancer Institute K25CA168984NCI NIH HHS K25 CA168984
6 · The paper itself

Abstract

backgroundEsophageal carcinoma is the eighth most common cancer in the world. Volumetric-modulated arc therapy (VMAT) is widely used to treat distal esophageal carcinoma due to high conformality to the target and good sparing of organs at risk (OAR). It is not clear if small-spot intensity-modulated proton therapy (IMPT) demonstrates a dosimetric advantage over VMAT. In this study, we compared dosimetric performance of VMAT and small-spot IMPT for distal esophageal carcinoma in terms of plan quality, plan robustness, and interplay effects.

methods35 distal esophageal carcinoma patients were retrospectively reviewed; 19 patients received small-spot IMPT and the remaining 16 of them received VMAT. Both plans were generated by delivering prescription doses to clinical target volumes (CTVs) on phase-averaged 4D-CT's. The dose-volume-histogram (DVH) band method was used to quantify plan robustness. Software was developed to evaluate interplay effects with randomized starting phases for each field per fraction. DVH indices were compared using Wilcoxon rank-sum test. For fair comparison, all the treatment plans were normalized to have the same CTV

resultsIn the nominal scenario, small-spot IMPT delivered statistically significantly lower liver D

conclusionsSmall-spot IMPT decreases doses to heart, liver, and total lung compared to VMAT as well as achieves clinically acceptable plan robustness. Our study supports the use of small-spot IMPT for the treatment of distal esophageal carcinoma.

Indexed as

AgedAged, 80 and overEsophageal NeoplasmsFemaleHumansMaleMiddle AgedOrgans at RiskPatient SelectionPrognosisProton TherapyRadiotherapy DosageRadiotherapy, Intensity-ModulatedRadiotherapy Planning, Computer-AssistedRetrospective Studiesdistal esophagealintensity-modulated proton therapyinterplay effectssmall spot sizevolumetric-modulated arc therapy

Identifiers

PMID31112371
PMCPMC6612702

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.